Contineum Therapeutics, Inc.
CTNM
Rank in Stocks
#13800
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company,... Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The companyโs lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Share Price
$10.30
Last synced: 2026-11-09
Market Cap
$364.14M
Change (1 day)
8.19%
Change (1 year)
-6.02%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Contineum Therapeutics, Inc. (CTNM)
Category
Healthcare
Operating Margin for Contineum Therapeutics, Inc. (CTNM)
Operating Margin as of November 2026 TTM: 0.00%
According to Contineum Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Contineum Therapeutics, Inc. from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -32.15% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Contineum Therapeutics, Inc.'s operating margin
What was Contineum Therapeutics, Inc.'s operating margin in 2025?
In 2025, Contineum Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Contineum Therapeutics, Inc.'s operating margin changed since 2021?
From 2021 to 2025, Contineum Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-32.15%).
How does Contineum Therapeutics, Inc.'s operating margin compare with similar companies?
Contineum Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.